This week in drug discovery (26-30 August)
News round-up for 26-30 August by DDW Senior Digital Content Editor Diana Spencer.
With the launch of an international clinical trial investigating BioNTech’s mRNA lung cancer vaccine announced this week, our news highlights focus on clinical trials, including studies of a monoclonal antibody and small molecule GLP-1 agonist for obesity, and a muscarinic M4 selective agonist for schizophrenia.
The top stories:
Monoclonal antibody CB1 inhibitor for obesity enters Phase II trials
Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody.
First patient dosed in UK novel cancer vaccine trial
A lung cancer patient at University College London Hospitals (UCLH) is the first to receive a novel cancer vaccine designed to prime the immune system to recognise and fight cancer cells.
Muscarinic M4 selective agonist shows promise in schizophrenia
Neurocrine Biosciences has revealed positive top-line data for its Phase II clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
Small molecule GLP-1 agonist shows superior tolerability
Yunovia has received permission from the Ministry of Food and Drug Safety (MFDS) of Korea to begin a Phase I study for its small molecule glucagon-like peptide-1 (GLP-1) agonist for obesity and diabetes.
